William Abraham, MD
- Cardiovascular Disease
Appointments: (614) 293-7677
About MeDr. Abraham earned his medical degree from Harvard Medical School in Boston, Massachusetts, following which he completed his residency in Internal Medicine and fellowships in Cardiovascular Disease and Advanced Heart Failure/Transplant Cardiology at the University of Colorado Health Sciences Center. He previously held leadership positions at the University of Colorado, the University of Cincinnati, and the University of Kentucky. At the Ohio State University, Dr. Abraham holds several leadership positions including an Associate Dean position, managing the College of Medicine’s non-cancer clinical and translational research portfolio. As Division Director, Dr. Abraham has developed one of the largest and most successful academic programs of Cardiovascular Medicine in the U.S.
Clinically, Dr. Abraham is board certified in Internal Medicine, Cardiovascular Diseases, and Advanced Heart Failure and Transplant Cardiology. He spends the majority of his clinical time managing heart failure patients in the inpatient and outpatient settings. Dr. Abraham has been recognized as one of the “Best Doctors in America” for fourteen consecutive years and has been ranked among the top 10% of physicians nationally in patient satisfaction.
Dr. Abraham’s research program focuses on elucidating basic mechanisms in heart failure and on clinical drug and device trials in heart failure. Dr. Abraham has received grants from the National Institutes of Health (NIH) including current NIH funding, the American College of Cardiology, and the Aetna Quality Care Foundation. He has made major contributions to advancing clinical science and patient care in heart failure in at least three areas: device development in heart failure; neurohormonal therapies in heart failure including beta-blockers, natriuretic peptides, and vasopressin receptor antagonists; and acute heart failure and renal dysfunction complicating heart failure. His work has contributed to the approval and adoption of several new therapies for heart failure, including beta-blockers, natriuretic peptides, cardiac resynchronization therapy, and implantable hemodynamic monitoring devices.
Dr. Abraham has authored more than 900 original papers, abstracts, book chapters, and review articles. His work has been published in high impact journals, including The New England Journal of Medicine, The Lancet, the Journal of the American Medical Association, Circulation, the European Heart Journal, and the Journal of the American College of Cardiology. Dr. Abraham has co-authored national heart failure practice guidelines and co-edited a leading textbook on heart failure entitled Heart Failure: A Practical Approach to Treatment and serves as series editor for the Color Atlas and Synopsis of Cardiovascular Medicine. Dr. Abraham serves on the editorial boards of several major journals. In 2014, 2015, and 2016, he was named to the Thomson Reuters Highly Cited Researchers list and as one of The World’s Most Influential Scientific Minds.
- Rated in the top 10 percent of physicians in the nation for patient satisfaction, 2014, 2017
- Named to the Castle Connolly list of America’s “Top Doctors” for 2017
- Best Doctor in America 2017
Specialties and conditions I treat
- Cardiovascular Disease
- Internal Medicine
- Heart Failure
- Heart-Assist Devices
- Cardiac Resynchronization Therapy
- Heart Transplantation
- Cardiovascular Diseases
- Coronary Care Units
Locations where I practice
Education and training
Harvard University School of Medicine
More about my work
University of Colorado School of Medicine
7/1/1990 - 11/30/1993
American Board of Internal Medicine
American Board of Internal Medicine (Subspecialty: Advanced Heart Failure & Transplant Cardiology)
American Board of Internal Medicine (Subspecialty: Cardiovascular)
News about me
- Ohio State Studies If High-tech Vest Can Help Manage Heart Failure at Home
- MedTips: Awards and Announcements
- December 2016 MedTips
- Implanted Device Successfully Treats Central Sleep Apnea, Study Finds
- Long-term Effects of Wireless Heart Failure Monitor Just Released
- International Consortium Creates Guidelines for Mitral Valve Repair Trials
- Study Finds Baroreflex Activation Therapy Effectively Treats Heart Failure
- Making Sense of Big Data for Improved Patient Care
- Study: New Device for Heart Failure Safely Improves Heart Function, Quality of Life
- Ohio State First to Implant Newly-Approved Wireless Heart Failure Monitor
- Study Finds Implanted Device Helps Patients With Central Sleep Apnea
- Cardiac Resynchronization Therapy Fails for Certain Heart Failure Patients
- Ohio Cardiologist Honored at Woman's Day Red Dress Award
- Some Heart Tests May Not Be Gauge for Best Treatment
- Bypass Surgery Gets Nod in Large Comparative Study
- Wireless Monitor Reduces Heart Failure Hospitalizations
- New Device May Help Heart Patients With Sleep Apnea
- January 2011 MedTips
- Ohio State Names Women's Cardiovascular Health Leader
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/28/2017, Dr. Abraham has reported financial relationships with the medical device, research and/or drug companies listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office at 614-293-7802.
- Abbott Laboratories
- Abbott Vascular
- Amgen, Inc.
- Arca Biopharma, Inc
- Cardiokinetix, Inc.
- Respicardia, Inc.
- Sunshine Heart, Inc.
- Edwards Lifesciences
- Zoll Medical Corp.